A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.
A 1-year safety study of dulaglutide in Japanese patients with Type 2 diabetes using a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial